Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020.

There has been an increasing trend of immuno-oncology drug research publications originating in China in the past decade and China has been ranked first globally for 18% of total research outputs in 2021 in this field. 54 It was also suggested that China might prioritize research on cancer with greater unmet clinical need. 54 Studie

also in 63,971 other papers